Increased Acetylcholinesterase Activity in Selected Regions of Rat Brain After Chronic (-)-deprenyl Administration

Overview

Journal Neurochem Res

Specialties Chemistry
Neurology

Date 1996 Oct 1

PMID 8923482

Authors

M K Lakshmana

S Jagadeesh

M N Subhash

Affiliations

Soon will be listed here.

Abstract

(-)-Deprenyl, 0.05, 1.0, 2.0, and 10.0 mg/kg body weight, was administered intraperitonially to Wistar rats for 30 days. The activity of acetylcholinesterase, and monoamine oxidase A and B were assayed in different brain regions. After the experimental period acetyl cholinesterase activity was found to be significantly increased in frontal cortex [P < 0.001] and hippocampus [P < 0.001] but not in striatum and brainstem at 0.1, 1.0, and 2.0 mg/kg dose, the maximum increase being at 0.1 mg/kg dose. Monoamine oxidase B activity was inhibited by more than 90% at 1.0, 2.0, and 10.0 mg/kg dose while 0.05 and 0.1 dose inhibited only about 55% and 70% respectively. Monoamine oxidase A activity was inhibited to more than 70% at 1.0 mg dose and to more than 90% at 2.0 and 10.0 mg/kg dose. At 0.05 and 0.1 mg/kg dose monoamine oxidase A activity was not significantly altered.

References

Tariot P, Sunderland T, Weingartner H, Murphy D, Welkowitz J, Thompson K . Cognitive effects of L-deprenyl in Alzheimer's disease. Psychopharmacology (Berl). 1987; 91(4):489-95. DOI: 10.1007/BF00216016. View

Inestrosa N, Soto C . Molecular biology of the amyloid of Alzheimer's disease. An overview. Biol Res. 1992; 25(2):63-72. View

Piccinin G, Finali G, Piccirilli M . Neuropsychological effects of L-deprenyl in Alzheimer's type dementia. Clin Neuropharmacol. 1990; 13(2):147-63. DOI: 10.1097/00002826-199004000-00004. View

Richfield E, Young A, Penney J . Comparative distribution of dopamine D-1 and D-2 receptors in the basal ganglia of turtles, pigeons, rats, cats, and monkeys. J Comp Neurol. 1987; 262(3):446-63. DOI: 10.1002/cne.902620308. View

Knoll J . The striatal dopamine dependency of life span in male rats. Longevity study with (-)deprenyl. Mech Ageing Dev. 1988; 46(1-3):237-62. DOI: 10.1016/0047-6374(88)90128-5. View

Finnegan K, Skratt J, Irwin I, DELANNEY L, Langston J . Protection against DSP-4-induced neurotoxicity by deprenyl is not related to its inhibition of MAO B. Eur J Pharmacol. 1990; 184(1):119-26. DOI: 10.1016/0014-2999(90)90672-s. View

Knoll J, Yen T, Miklya I . Sexually low performing male rats die earlier than their high performing peers and (-)deprenyl treatment eliminates this difference. Life Sci. 1994; 54(15):1047-57. DOI: 10.1016/0024-3205(94)00415-3. View

Cohen G, Spina M . Deprenyl suppresses the oxidant stress associated with increased dopamine turnover. Ann Neurol. 1989; 26(5):689-90. DOI: 10.1002/ana.410260518. View

Mann J, Aarons S, Wilner P, Keilp J, Sweeney J, Pearlstein T . A controlled study of the antidepressant efficacy and side effects of (-)-deprenyl. A selective monoamine oxidase inhibitor. Arch Gen Psychiatry. 1989; 46(1):45-50. DOI: 10.1001/archpsyc.1989.01810010047007. View

10.

Knoll B, Held G, Gyarmati Z . The effect of selective MAO inhibitors on the conditioned avoidance response of Wistar rats. Pol J Pharmacol Pharm. 1977; 29(3):291-6. View

11.

Carrillo M, Kanai S, Nokubo M, Ivy G, Sato Y, Kitani K . (-)Deprenyl increases activities of superoxide dismutase and catalase in striatum but not in hippocampus: the sex and age-related differences in the optimal dose in the rat. Exp Neurol. 1992; 116(3):286-94. DOI: 10.1016/0014-4886(92)90008-e. View

12.

Paterson I, Juorio A, Berry M, Zhu M . Inhibition of monoamine oxidase-B by (-)-deprenyl potentiates neuronal responses to dopamine agonists but does not inhibit dopamine catabolism in the rat striatum. J Pharmacol Exp Ther. 1991; 258(3):1019-26. View

13.

Bradford M . A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976; 72:248-54. DOI: 10.1016/0003-2697(76)90527-3. View

14.

. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med. 1993; 328(3):176-83. DOI: 10.1056/NEJM199301213280305. View

15.

Kitani K, Kanai S, Sato Y, Ohta M, Ivy G, Carrillo M . Chronic treatment of (-)deprenyl prolongs the life span of male Fischer 344 rats. Further evidence. Life Sci. 1993; 52(3):281-8. DOI: 10.1016/0024-3205(93)90219-s. View

16.

Dunnett S, Fibiger H . Role of forebrain cholinergic systems in learning and memory: relevance to the cognitive deficits of aging and Alzheimer's dementia. Prog Brain Res. 1993; 98:413-20. DOI: 10.1016/s0079-6123(08)62425-5. View

17.

Bareggi S, Giacobini E . Acetylcholinesterase activity in ventricular and cisternal CSF of dogs: effect of chlorpromazine. J Neurosci Res. 1978; 3(5-6):335-9. DOI: 10.1002/jnr.490030504. View

18.

Naoi M, Nagatsu T . Inhibition of monoamine oxidase by 3,4-dihydroxyphenylserine. J Neurochem. 1986; 47(2):604-7. DOI: 10.1111/j.1471-4159.1986.tb04542.x. View

19.

Ellman G, COURTNEY K, ANDRES Jr V, FEATHER-STONE R . A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol. 1961; 7:88-95. DOI: 10.1016/0006-2952(61)90145-9. View

20.

Fishman E, Siek G, MacCallum R, BIRD E, Volicer L, Marquis J . Distribution of the molecular forms of acetylcholinesterase in human brain: alterations in dementia of the Alzheimer type. Ann Neurol. 1986; 19(3):246-52. DOI: 10.1002/ana.410190305. View